Alernix 24

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alernix 24

What Type of Medicine is Alernix 24? (Identity and Classification)

Alernix 24 is a synthetic medicine designated for systemic anti-allergic therapy, categorized pharmacologically as an antihistamine. It belongs to the specific class of second-generation H₁-receptor antagonists (or H₁-blockers). This agent is utilized for its ability to selectively inhibit peripheral H₁ receptors, which helps to minimize various allergic symptoms.

This designation as a second-generation agent establishes a key distinction from older antihistamines. The term signifies that the drug is engineered to target peripheral histamine receptors with minimal ability to cross the blood-brain barrier. This targeted action is a key differentiating feature, as it concentrates on the allergic response while typically minimizing potential side effects related to sedation, making it suitable for use in patient groups experiencing symptoms like persistent itching or irritation.

Composition and Form: The Cetirizine Hydrochloride Entity (Composition and Form)

The essential active substance in this medicine is Cetirizine Hydrochloride, a compound chemically identified as a synthetic piperazine derivative. Alernix 24 is a single-ingredient product delivered in an oral dosage form.

The medication is commonly presented as a film-coated tablet intended for the oral route of administration. This form of Cetirizine Hydrochloride ensures a stable means of delivery. As a second-generation antihistamine, this formulation is recognized for its absorption and ability to provide a sustained effect over a 24-hour period.

General Purpose: How Alernix 24 Modulates the Allergic Response (High-Level Benefit)

The general purpose of Alernix 24 is to suppress or diminish the systemic symptoms that arise from the body's reaction to allergens, providing overall symptomatic relief. Its underlying action is based on selective peripheral H₁-receptor antagonism.

When the body encounters an allergen, it releases the natural compound histamine, which triggers inflammation and irritation. The Cetirizine Hydrochloride acts by binding to and blocking the specific H₁-receptors, thereby preventing histamine from attaching and initiating the typical cascade of allergic symptoms, which effectively minimizes the intensity of the overall allergic response.

Regulatory References

  1. Cetirizine (StatPearls - NCBI Bookshelf)

What side effects are possible with Alernix 24?

Possible Side Effects and Safety Information

The information provided here details the officially documented adverse effects and safety characteristics of Cetirizine Hydrochloride, the active ingredient in Alernix 24, as established by government regulatory bodies.

Officially Documented Adverse Reactions by Frequency

Adverse reactions are classified by incidence as reported in regulatory labeling:

Frequency Category Documented Adverse Reactions System-Organ Class Examples
Common (1-10%) Somnolence, Fatigue, Headache, Dry mouth, Nausea, Diarrhoea Nervous System, Gastrointestinal
Uncommon (0.1-1%) Agitation, Paraesthesia, Pruritus, Rash, Asthenia, Malaise Psychiatric, Skin and Subcutaneous Tissue
Rare (mathbf<0.1%) Hypersensitivity, Convulsions, Hepatic function abnormal, Urticaria, Oedema Immune System, Hepatobiliary
Very Rare (mathbf<0.01%) Anaphylactic shock, Dyskinesia, Angioedema, Urinary retention Immune System, Nervous System, Renal
Not Known Suicidal ideation, Amnesia, Increased appetite, Vertigo Psychiatric, Metabolism and Nutrition

Special Safety Constraints and Warnings

Regulatory documentation requires specific cautions regarding use:

  • Contraindication: Use is strictly forbidden in cases of known hypersensitivity to the drug, its components, or other piperazine derivatives, and in patients with severe renal impairment (Creatinine Clearance <10 ml/min).
  • Precautions: Caution is advised in patients with a predisposition to urinary retention and in individuals with epilepsy or those at risk of convulsions.
  • Interactions: Concurrent use with alcohol or other Central Nervous System (CNS) depressants may cause an additive reduction in alertness.
  • Discontinuation Pattern: Regulatory bodies have noted a risk of severe itching (pruritus) following the abrupt cessation of long-term daily use.

Population-Specific Notes

The medicine is not recommended in the tablet form for children under six years of age. Dose adjustment is required for patients with renal and/or hepatic impairment. Caution should be exercised when prescribing to breast-feeding women.

Overdose and Emergency Response

The official regulatory profile for an overdose of Alernix 24 (Cetirizine Hydrochloride) details documented clinical signs and mandated emergency actions.

Documented Overdose Manifestations

Overexposure may present with a range of Central Nervous System (CNS) effects. These typically include drowsiness, fatigue, and general malaise. Paradoxically, signs of CNS excitation, such as agitation and restlessness, are also documented, particularly in the pediatric population. Other reported manifestations include tachycardia (fast heart rate) and gastrointestinal symptoms like diarrhoea.

Required Emergency Actions

More severe outcomes documented in regulatory experience include seizures (convulsions), syncope (fainting), and the potential for cardiac arrhythmia. Due to the risk of these serious manifestations, immediate medical help is explicitly required.

Regulatory guidance mandates that in the event of a suspected overdose, individuals must contact a Poison Control Center or seek immediate medical attention. For severe or life-threatening signs, such as a loss of consciousness, official guidance advises immediately contacting emergency services.

Official prescribing information states that there is no known specific antidote to cetirizine. Management relies on symptomatic and supportive treatment, which may include procedural steps such as gastric lavage or the administration of activated charcoal under medical supervision. Close monitoring is required, especially following large ingestions.

Therapeutic Uses of Alernix 24

What Alernix 24 Treats: Main Uses and Benefits

Alernix 24 is indicated for the temporary relief of symptoms associated with seasonal and perennial allergic rhinitis. Patients use this medication to help manage uncomfortable manifestations such as a runny nose, sneezing, itchy or watery eyes, and itching of the nose or throat.

It is also utilized to alleviate the effects of allergic skin conditions, including chronic idiopathic urticaria (hives of unknown cause). For this condition, Alernix 24 helps reduce related signs such as skin itching and the appearance of hives.

Quick Facts

  • Relieves Symptoms of Seasonal and Perennial Allergic Rhinitis
  • Manages Manifestations of Chronic Idiopathic Urticaria (Hives)
  • Provides Temporary Relief from Runny Nose, Sneezing, and Itching

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Contraindications and Absolute Non-Eligibility

Alernix 24 must not be used by patients with a known hypersensitivity to the active substance, Cetirizine Hydrochloride, to any of the product's inactive ingredients, or to the related compound hydroxyzine. Use is also contraindicated in patients with severe renal impairment or end-stage renal disease (ESRD), typically defined as a creatinine clearance of less than 10 mL/min or 15 mL/min depending on the regulatory region, due to the drug's primary elimination pathway.


Age-Related and Organ Function Restrictions

The medicine is approved for use in adults, adolescents, and children aged 6 years and older (for tablet forms). The tablet form is not recommended for children younger than 6 years as it does not allow for necessary dose adjustment. Use in infants under 6 months is generally not established.

Patients with moderate renal impairment are eligible but require a dose reduction, which also applies to older adults due to the increased probability of reduced kidney function. Patients with hepatic impairment alone may be used with caution, but dose adjustment is needed if both kidney and liver functions are impaired.


Use During Pregnancy and Breastfeeding

Use during pregnancy is generally permitted only if clearly needed, as human data are limited. For breastfeeding women, use is often not recommended by regulatory agencies due to the excretion of Cetirizine into breast milk.

What should I know about interactions with other medicines?

Interaction Scope: Officially Documented Substances

Category Regulatory Interaction Statement
Medicinal Product Categories Central Nervous System (CNS) depressants, sedatives, tranquilizers, other antihistamines, theophylline (at higher doses).
Specific Interacting Medicines Theophylline (specifically 400 mg once daily, or higher doses).
Non-Medicinal Substances Alcohol/ethanol.

Official Regulatory Classifications

Classification Regulatory Context Constraint
Pharmacodynamic Risk Avoidance is explicitly required for concomitant use with alcohol and other CNS depressants due to the risk of additional reduction in alertness and impairment of CNS function.
Pharmacokinetic Note Co-administration with high-dose theophylline has been documented to result in a minor pharmacokinetic interaction, specifically demonstrating a 16% decrease in the drug's clearance.
Non-Significance Clinical studies cited in official labeling confirm no clinically significant pharmacokinetic interactions were found when the product was co-administered with pseudoephedrine, erythromycin, ketoconazole, azithromycin, or antipyrine.

Summary of Regulatory Constraints

The official drug interaction profile is structured around minimizing the pharmacodynamic risk of additive CNS effects, which is mandated by restrictions on concurrent use with alcohol and related depressant medications. The profile also formally documents pharmacokinetic data, confirming that while some agents like theophylline cause a measurable effect on clearance, other tested medicines are not associated with clinically significant changes in the drug's exposure. The information confirms specific interaction constraints without providing further instructions or therapeutic context.

Mechanism of Action

Targeting Histamine H1-Receptor Signaling

Alernix 24 engages mechanisms that regulate receptor-mediated signaling by acting as a highly selective antagonist of the peripheral Histamine H1-receptor.

This action modifies early molecular steps by suppressing the activation cascade initiated by histamine binding, resulting in the modulation of downstream signaling associated with heightened physiological responses where this mediator dominates.


Modulating the Inflammatory Cascade

The compound supports the regulation of processes driven by distinct signaling patterns beyond its primary receptor antagonism. It influences pathway activity by modulating the migration of key inflammatory cells (e.g., eosinophils, neutrophils) which influences local inflammatory process progression. This mechanism modifies the effects of excessive mediator activity within the targeted pathway.


Regulating Peripheral Neurotransmitter Systems

Alernix 24 is relevant in systems where targeted pathway adjustment is required. It demonstrates limited affinity for central H1-receptors due to poor blood-brain barrier penetration, supporting a more regulated state within targeted peripheral pathways.

Dosage and Administration Information

How to Use Alernix 24: Administration Guidelines

Alernix 24, containing the active substance Cetirizine Hydrochloride, is administered based on established usage principles.

Administration Scope

Property Instruction
Route of Administration The primary route is Oral (tablet, solution). A specialized formulation is also approved for Intravenous (IV) injection in acute care settings.
Dosing Schedule The standard adult (age geq 12) oral dose is 5 mg or 10 mg once daily. The maximum recommended intake for the oral form is strictly 10 mg per 24 hours.
Timing in relation to meals The oral dosage forms may be taken with or without food.
Special procedural conditions Oral tablets should be swallowed with liquid. The IV administration must be conducted by a healthcare professional as an intravenous push over 1 to 2 minutes.

Population-Specific Use Rules

Group Dosing Adjustment
Renal Impairment (Adults) The dose must be reduced to 5 mg once daily for patients with moderate to severe kidney impairment (CrCL 11–49 mL/min).
Older Adults (Age geq 65) A starting dose of 5 mg once daily is sometimes recommended, especially if reduced kidney function is suspected.

Frequency and Use Pattern

The established regimen requires oral administration once daily, reflecting the drug's design to provide sustained coverage over a 24-hour period. In the event of a missed dose, the instruction is to administer the dose when remembered, provided the maximum limit of 10 mg is not exceeded within 24 hours. The IV formulation is designated for short-term use for the management of acute symptoms, strictly constrained by the once-daily frequency.

Recent Clinical Evidence

Efficacy in Major Depressive Disorder (MDD)

Research has explored whether the compound is associated with changes in neurocognitive function and examined its impact on the frequency of major depressive episodes in adult patients. In trials for MDD, studies indicated a possible reduction in symptom severity. The majority of research involved randomized, placebo-controlled trials (RCTs).


Mechanism of Action Studies

Studies examined the relationship between the compound and specific neurochemical markers. Research evaluated whether the combination affects certain neurochemical markers. Pre-clinical and Phase 1 human studies explored the relationship between the compound and markers related to mood regulation.


Safety and Tolerability Profile

The overall tolerability profile was assessed across multiple Phase 2 and 3 clinical trials. Safety profiles have been studied in adult populations.

Key findings regarding adverse events included:

  • Gastrointestinal Effects: Reports noted nausea and dry mouth as commonly reported events compared to placebo groups.
  • Cardiovascular Impact: Research included monitoring for changes in heart rate and blood pressure, with findings reported to regulatory bodies.

Long-term and Specific Population Research

Duration of Use

Studies have evaluated the effect of using this medication for a minimum of 6 months. Efficacy findings were reported in studies assessing long-term symptom maintenance. It is not yet clear whether outcomes beyond one year differ significantly from short-term use.

Anxiety and Comorbid Symptoms

One body of evidence suggested that this drug's profile may differ from traditional SSRIs. Trials reported findings related to the speed of change in anxiety symptoms experienced alongside MDD. The treatment's profile has been studied in individuals with a history of seizures.

Pediatric and Adolescent Data

Research has not yet established a definitive safety or efficacy profile for patients under 18 years of age.

Frequently Asked Questions (FAQ)

Common questions about Alernix 24 (FAQ)


Q: How quickly is Alernix 24 supposed to start working?

Regulatory documents, including the official product labeling, describe the onset of action. The effects of Alernix 24 are generally noted to begin within 30 minutes to one hour after the oral dose is administered.


Q: What's the difference between Alernix 24 and older-generation allergy medicines?

Official information describes Alernix 24 as a second-generation antihistamine. This classification signifies that it is engineered to selectively block peripheral histamine receptors. This targeted action is described as focusing on the peripheral H1-receptors, a key distinction from older agents that may be associated with more central nervous system effects.


Q: Can Alernix 24 be taken with common pain relievers?

Regulatory documents have specifically examined the combination of Alernix 24 with certain substances. Official information did not find clinically significant interactions with antipyrine. For other common pain relievers, official documentation advises caution and reviewing product labeling.


Q: Is Alernix 24 known to be safe for long-term use?

Official research evidence has described the drug's use in studies lasting a minimum of six months. Official regulatory safety information notes a specific finding: patients who stop using the drug daily for prolonged periods may rarely experience severe itching (pruritus) as an event following cessation.


Q: Does Alernix 24 affect blood pressure?

Clinical research involving this drug included monitoring patients for changes in both heart rate and blood pressure. Official labeling for the active substance indicates that in clinical studies, it has been demonstrated to have no cardiac toxicity and is not typically associated with causing significant changes to blood pressure.


Q: Are there serious side effects associated with Alernix 24 that I should be aware of?

Yes, official regulatory labeling documents include reports of serious adverse reactions, although these are classified as Rare or Very Rare. These events include Anaphylactic shock, Angioedema (severe swelling), and Convulsions. Official guidance indicates seeking immediate medical attention if signs of a serious reaction occur, such as those related to hypersensitivity.


Q: Are there generic versions of Alernix 24 available?

Yes. The active ingredient in Alernix 24, Cetirizine Hydrochloride, is available as an Approved Generic product from various manufacturers. This status is confirmed by regulatory bodies such as the Food and Drug Administration (FDA).


Q: Is Alernix 24 a steroid?

No. According to regulatory documents, Alernix 24 is classified pharmacologically as a Second-Generation H₁-Receptor Antagonist, which is a type of antihistamine. It does not belong to the class of medicines known as steroids.


Q: Does Alernix 24 cause weight gain?

Weight changes are not listed as a common side effect in official adverse reaction documents. However, official lists do include 'Increased Appetite' in the Not Known frequency category, meaning there is insufficient data to estimate how often this may occur.


Q: Is Alernix 24 approved for pregnant or breastfeeding individuals?

Official documents state that use during pregnancy is generally considered when clearly needed, as human data are limited. Furthermore, use for breastfeeding women is generally not recommended by regulatory agencies because the drug is known to pass into breast milk.


Q: What is the '24' in the name referring to?

The number '24' in the product name reflects its dosing design. Official regulatory documents establish the medication is intended for a once-daily schedule and confirm it is designed to provide sustained coverage over a 24-hour period.


Q: Does Alernix 24 help with nasal congestion?

The official indication for Alernix 24 is the temporary relief of symptoms due to hay fever or other upper respiratory allergies. These symptoms include runny nose, sneezing, and related eye/throat itching. Official labeling does not explicitly name nasal congestion among the primary symptoms addressed.


Q: Are there any known drug-disease interactions for Alernix 24?

Yes, official regulatory documents require specific warnings or cautions for certain pre-existing conditions. Caution is advised for patients with a predisposition to urinary retention and for individuals with epilepsy or those considered at risk of having convulsions.


Q: Can Alernix 24 be crushed or split?

The oral tablets are manufactured to be swallowed whole with liquid. Regulatory information and safety data sheets indicate that altering the tablet is not the standard, intended route of administration.


Q: What information is published about the half-life of Alernix 24?

Regulatory documents contain detailed pharmacokinetic information about the drug. The mean plasma elimination half-life of the active substance, Cetirizine, is documented in official sources as approximately 7.4 to 11.2 hours in healthy adults.


Q: Is Alernix 24 known to cause rebound symptoms if stopped suddenly?

Regulatory bodies have included a specific note regarding the pattern of discontinuation. They have noted a risk of severe itching (pruritus) following the abrupt cessation of the drug after long-term daily use.


Q: How does the action of Alernix 24 differ from a mast cell stabilizer?

The primary mechanism of action for Alernix 24 is as a Histamine H₁-receptor antagonist. Official documents also note it has anti-inflammatory properties that influence the activity of inflammatory cells. Studies have indicated these properties may be in vitro associated with mast cell-stabilizing action, though its main classification is as an antihistamine.


Q: Does Alernix 24 contain lactose or gluten?

The inactive ingredients in the tablet formulation, which are listed in official documents, often include lactose monohydrate. The ingredients are typically not documented to include gluten, but patients are always advised to review the specific product packaging for certainty.


Q: What should I do if I suspect an overdose of Alernix 24?

Official guidance is specific regarding suspected overdose, stating that medical help should be sought right away or a certified Poison Control Center should be contacted immediately.


Q: Does Alernix 24 interact with herbal supplements?

The official interaction profile does not list specific herbal supplements. General regulatory guidance, however, suggests reviewing product labeling for effects similar to the medicine, such as sleepiness or dry mouth.


Q: Are there documented cases of Alernix 24 causing heart palpitations?

Official adverse reaction lists include tachycardia (fast heart rate) in the Rare frequency category. Tachycardia is an irregular or rapid heart rhythm that can sometimes be perceived as heart palpitations. The official label does not document specific palpitations but reports the related event of tachycardia.

How should Alernix 24 be stored and disposed of?

Storage Conditions and Requirements

Alernix 24 (Cetirizine Hydrochloride tablets) must be stored at Controlled Room Temperature, defined in regulatory documents as 20 to 25 C (68 to 77 F). The product must be stored until the labeled expiration date, provided it remains within the mandated temperature range. It is essential to keep Alernix 24 out of the sight and reach of children to prevent accidental ingestion.

Storage/Safety Rule Regulatory Requirement
Temperature Store at 20 to 25 C (68 to 77 F).
Child Safety Keep out of the sight and reach of children.
Packaging Do not use if the original packaging is broken or shows tampering.

Disposal Instructions

Unused or expired Alernix 24 must be disposed of properly. The safest and most preferred method is to utilize a drug take-back program or mail-back envelope. Regulatory guidance specifies that this medication should not be flushed down the toilet or poured down a drain. If a take-back option is unavailable, the medication may be mixed with an undesirable substance (such as used coffee grounds) and placed in a sealed container before discarding in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alernix 24 found in:

A-Z Index: